|Grant Number:||3U01CA093332-05S3 Interpret this number|
|Primary Investigator:||Weeks, Jane|
|Organization:||Dana-Farber Cancer Inst|
|Project Title:||Lung/Colon Cancer Outcomes-Cancer Research Network|
We will accrue all patients with newly diagnosed lung or colon cancer receiving their care in one of five geographically diverse sites in the Cancer Research Network, an NCI-funded research consortium of HMOs. Automated data for all patients (2,058 patients with lung cancer over the two year enrollment period, and 1,732 patients with colon cancer over the two year enrollment period) will be supplemented with data obtained from complete medical record review and patient surveys for a sample of 1,424 patients with newly diagnosed lung cancer and 1,222 patients with newly diagnosed colon cancer. We will oversample African-Americans, Asians and Pacific Islanders, as well as Medicaid recipients. In addition, we will assemble an inception cohort of patients with newly diagnosed metastatic recurrences of colorectal cancer during the two-year enrollment period (projected at approximately 300 patients) for comprehensive data collection. We propose to lead analyses of CanCORS-wide core data in order to (1) examine the effect of race and ethnicity on patterns of care, treatment choice, quality of life, symptom control, and satisfaction; (2) characterize the types of providers seen by patients and examine the associations between provider characteristics/attitudes and patterns of care and outcomes; (3) evaluate the relationship between the structure/function of cancer care in the health care delivery systems of participating patients and patient outcomes, including health status, patient satisfaction, and cost; and (4) generate estimates of utility weights and time- and out-of-pocket costs that are disease- and treatment-specific for use in future cost-effectiveness analyses. Finally, in a Special Research Study we will aggregate cost data for CRN CanCORS subjects in order to (1) determine cancer-attributable phase-specific and lifetime costs of care for colorectal and lung cancer; (2) determine the proportion of total cancer-attributable costs that are spent on initial therapy versus second- and third line therapies for each cancer, stratified by stage at diagnosis; and (3) determine the relationship between type of initial therapy and the subsequent lifetime cancer-attributable costs of care.
Enrollment of patients with lung and colorectal cancers onto clinical trials.
Authors: Fouad MN, Lee JY, Catalano PJ, Vogt TM, Zafar SY, West DW, Simon C, Klabunde CN, Kahn KL, Weeks JC, Kiefe CI
Source: J Oncol Pract, 2013 Mar;9(2), p. e40-7.
Racial variation in the cancer caregiving experience: a multisite study of colorectal and lung cancer caregivers.
Authors: Martin MY, Sanders S, Griffin JM, Oster RA, Ritchie C, Phelan SM, Atienza AA, Kahn K, van Ryn M
Source: Cancer Nurs, 2012 Jul-Aug;35(4), p. 249-56.
Economic burden for informal caregivers of lung and colorectal cancer patients.
Authors: Van Houtven CH, Ramsey SD, Hornbrook MC, Atienza AA, van Ryn M
Source: Oncologist, 2010;15(8), p. 883-93.
EPub date: 2010 Jul 28.
Objective burden, resources, and other stressors among informal cancer caregivers: a hidden quality issue?
Authors: van Ryn M, Sanders S, Kahn K, van Houtven C, Griffin JM, Martin M, Atienza AA, Phelan S, Finstad D, Rowland J
Source: Psychooncology, 2011 Jan;20(1), p. 44-52.
Looking back from death: the value of retrospective studies of end-of-life care.
Authors: Earle CC, Ayanian JZ
Source: J Clin Oncol, 2006 Feb 20;24(6), p. 838-40.
Understanding cancer patients' experience and outcomes: development and pilot study of the Cancer Care Outcomes Research and Surveillance patient survey.
Authors: Malin JL, Ko C, Ayanian JZ, Harrington D, Nerenz DR, Kahn KL, Ganther-Urmie J, Catalano PJ, Zaslavsky AM, Wallace RB, Guadagnoli E, Arora NK, Roudier MD, Ganz PA
Source: Support Care Cancer, 2006 Aug;14(8), p. 837-48.
EPub date: 2006 Feb 16.
Understanding cancer treatment and outcomes: the Cancer Care Outcomes Research and Surveillance Consortium.
Authors: Ayanian JZ, Chrischilles EA, Fletcher RH, Fouad MN, Harrington DP, Kahn KL, Kiefe CI, Lipscomb J, Malin JL, Potosky AL, Provenzale DT, Sandler RS, van Ryn M, Wallace RB, Weeks JC, West DW
Source: J Clin Oncol, 2004 Aug 1;22(15), p. 2992-6.